Data / Form D filings / Medication Review, Inc.
Medication Review, Inc.: Form D filings
Medication Review, Inc., a pharmaceuticals company in Spokane, WA, filed 2 Form D notices with the SEC between 2010 and 2012. The latest, on March 22, 2012, reports $12,000 sold of a $2.5 million offering to 1 investor.
Find out what Medication Review, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 104 S. FREYA, Suite 217 White Flag Building, Spokane, WA, 99202
- Phone
- (509) 343-5200
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Washington
- Revenue range
- $1,000,001 - $5,000,000
- Exemptions claimed
- Rule 506, Securities Act section 4(6)
- SEC identifier (CIK)
- 1497310
The full lists. Form D filings in Washington: 1,095 rows, $54.75, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 22, 2012 | New notice | $2,500,000 | $12,000 | $2,488,000 | 1 | Mar 19, 2012 | sec.gov |
| Sep 21, 2010 | New notice | $400,000 | $195,000 | $205,000 | 6 | Sep 15, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| K. Douglas Crafton | Executive Officer, Director | |
| Tom R. Jensen, MPA | Director | |
| Christopher R Terriff, RPh | Executive Officer | |
| James F Karel, MS | Director | |
| Mary R Giannini | Director | |
| Michael R. Anderegg | Executive Officer | |
| Kyle R Downey, PharmD | Executive Officer | |
| Linda F Garrelts-MacLean, BPharm, RPh | Director |
Other pharmaceuticals companies in Washington that filed recently
- Aptevo Therapeutics Inc. $3.5 million · Aug 26, 2026
Every Form D from the week of Mar 19, 2012 · All recent filings in Washington · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Medication Review, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.